Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Gross Profit: 2020-2025

Historic Gross Profit for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $90.2 million.

  • Pharming Group N.V's Gross Profit rose 32.61% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $391.2 million, marking a year-over-year increase of 53.14%. This contributed to the annual value of $261.8 million for FY2024, which is 18.94% up from last year.
  • As of Q3 2025, Pharming Group N.V's Gross Profit stood at $90.2 million, which was down 40.83% from $152.5 million recorded in Q2 2025.
  • Pharming Group N.V's Gross Profit's 5-year high stood at $177.6 million during Q4 2021, with a 5-year trough of -$83.6 million in Q3 2021.
  • For the 3-year period, Pharming Group N.V's Gross Profit averaged around $72.5 million, with its median value being $67.1 million (2024).
  • As far as peak fluctuations go, Pharming Group N.V's Gross Profit tumbled by 272.89% in 2021, and later soared by 107,696.80% in 2022.
  • Pharming Group N.V's Gross Profit (Quarterly) stood at $177.6 million in 2021, then crashed by 72.78% to $48.3 million in 2022, then spiked by 53.26% to $74.1 million in 2023, then increased by 8.58% to $80.5 million in 2024, then spiked by 32.61% to $90.2 million in 2025.
  • Its Gross Profit was $90.2 million in Q3 2025, compared to $152.5 million in Q2 2025 and $80.5 million in Q4 2024.